



**5<sup>th</sup> August 2021**

## **dorsaVi extends agreement with Medtronic**

### **Key highlights**

- **dorsaVi has extended its agreement with Medtronic for a further 5 months, worth an additional ~US\$171k**
- **The extended agreement aims to optimise the technology and build on insights from the ongoing master service agreement, announced in March 2021**
- **The exciting partnership with Medtronic continues to build on the initial evaluation agreement announced in December 2020**

**Melbourne, Australia, 5<sup>th</sup> August 2021:** dorsaVi (ASX: DVL) (**dorsaVi** or the Company) is pleased to announce it has extended its agreement with Medtronic for a further 6 months, following continued success of the partnership.

The agreement extension is worth ~US\$171k, on top of ~US\$330k from the master service agreement (MSA) announced in March 2021. Building on from the insights generated in the MSA, dorsaVi will continue to leverage its technology in the data capture and analysis workstreams, leading to an optimised, customisable product, in line with Medtronic's objectives.

This partnership further validates dorsaVi's technology, as a leading international healthcare organisation continues to rely on the data-driven insights generated by the Company to deliver better patient outcomes.

### **Dr Andrew Ronchi, dorsaVi's Chief Executive Officer, said:**

*"We are excited to continue developing our relationship with Medtronic. The extension of our agreement is testament to the hard work of our team and is a strong validation of our world-leading technology. We will continue to invest in this partnership and build upon our growing foundation. This agreement further highlights the different potential uses of our technology, exploring new applications and potential partnerships to deliver shareholder value."*

Medtronic plc, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health, and extending life for millions of people around the world.

– ENDS –

**For further information about dorsaVi, please contact:**

**dorsaVi**

Andrew Ronchi  
Chief Executive Officer  
+61 417 882 267  
[ar@dorsavi.com](mailto:ar@dorsavi.com)

**Investor Enquiries**

Dean Dribbin  
Vesparum Capital  
+61 3 8582 4800  
[dorsavi@vesparum.com](mailto:dorsavi@vesparum.com)

The release of this announcement was authorised by the Disclosure Committee of the dorsaVi Board.

**About dorsaVi**

dorsaVi Ltd (ASX: DVL) is an ASX company focused on developing innovative motion analysis device technologies for use in clinical applications, elite sports, and occupational health and safety. dorsaVi believes its wearable sensor technology enables, for the first time, many aspects of detailed human movement and position to be accurately captured, quantified and assessed outside a biomechanics lab, in both real-time and real situations for up to 24 hours. dorsaVi's focus is on two major markets:

- **Workplace:** dorsaVi enables employers to assess risk of injury for employees as well as test the effectiveness of proposed changes to OHS workplace design, equipment or methods based on objective evidence. dorsaVi works either directly with major corporations, or through an insurance company's customer base with the aim of reducing workplace compensation and claims. dorsaVi has been used by major corporations including Sodexo, London Underground, Vinci Construction, Crown Resorts, Caterpillar (US), Monash Health, Coles, Woolworths, Toll, Toyota, Orora (formerly Amcor) and BHP Billiton.
- **Clinical:** dorsaVi is transforming the management of patients with its clinical solutions (ViMove, ViMove2 and Professional Suite) which provide objective assessment, monitoring outside the clinic and immediate biofeedback. The clinical market is broken down into the physical therapy (physiotherapists) market, hospital in the home and elite sports. Hospital in the home refers to the remote management of patients by clinicians outside of physical therapy (i.e. for orthopaedic conditions). Elite sports refers to the management and optimisation of athletes through objective evidence for decisions on return to play, measurement of biomechanics and immediate biofeedback to enable peak performance. dorsaVi's ViPerform is being used in the U.S. by the National Basketball Association (NBA), the Major League Soccer (MLS) and the National Football League (NFL). It is also used by the AFL and NRL clubs in Australia, by the English Premier League (EPL) clubs, England and Wales Cricket Board and the Board of Control for Cricket in India as well as various Olympic teams and athletes internationally. dorsaVi's Telehealth provides a virtual clinic, enabling clinicians to do business differently and take their patient consultations online.

Further information is available at [www.dorsavi.com](http://www.dorsavi.com)